Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: Role in angiogenesis and prognosis

Clinical Cancer Research

Volumn 9, Issue 2, 2003, Pages 853-860

  White, Eric S ^a   Flaherty, Kevin R ^a   Carskadon, Shannon ^a   Brant, Ashley ^a   Iannettoni, Mark D ^b   Yee, John ^b   Orringer, Mark B ^b   Arenberg, Douglas A ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; MACROPHAGE MIGRATION INHIBITION FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MEASUREMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN MOTIF; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMOKINES, CXC; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; LUNG NEOPLASMS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; NEOVASCULARIZATION, PATHOLOGIC; RECURRENCE; REFERENCE VALUES;

EID: 0037314803     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Bloom, B. R., and Bennett, B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science (Wash. DC), 153: 80-82, 1966.
2. David, J. R. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc. Natl. Acad. Sci. USA, 56: 72-77, 1966.
3. Weiser, W. Y., Temple, P. A., Witek-Giannotti, J. S., Remold, H. G., Clark, S. C., and David, J. R. Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proc. Natl. Acad. Sci. USA, 86: 7522-7526, 1989.
4. Bernhagen, J., Calandra, T., Mitchell, R. A., Martin, S. B., Tracey, K. J., Voelter, W., Manogue, K. R., Cerami, A., and Bucala, R. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature (Lond.), 365: 756-759, 1993.
5. Bozza, M., Satoskar, A. R., Lin, G., Lu, B., Humbles, A. A., Gerard, C., and David, J. R. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J. Exp. Med., 189: 341-346, 1999.
6. Calandra, T., Echtenacher, B., Roy, D. L., Pugin, J., Metz, C. N., Hultner, L., Heumann, D., Mannel, D., Bucala, R., and Glauser, M. P. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat. Med., 6: 164-170, 2000.
7. Leech, M., Metz, C., Santos, L., Peng, T., Holdsworth, S. R., Bucala, R., and Morand, E. F. Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum., 41: 910-917, 1998.
8. Leech, M., Metz, C., Hall, P., Hutchinson, P., Gianis, K., Smith, M., Weedon, H., Holdsworth, S. R., Bucala, R., and Morand, E. F. Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum., 42: 1601-1608, 1999.
9. Korsgren, M., Kallstrom, L., Uller, L., Bjerke, T., Sundler, F., Persson, C. G., and Korsgren, O. Role of macrophage migration inhibitory factor (MIF) in allergic and endotoxin-induced airway inflammation in mice. Mediators Inflamm., 9: 15-23, 2000.
10. Rossi, A. G., Haslett, C., Hirani, N., Greening, A. P., Rahman, I., Metz, C. N., Bucala, R., and Donnelly, S. C. Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF). Potential role in asthma. J. Clin. Investig., 101: 2869-2874, 1998.
11. Abe, R., Shimizu, T., Ohkawara, A., and Nishihira, J. Enhancement of macrophage migration inhibitory factor (MIF) expression in injured epidermis and cultured fibroblasts. Biochim. Biophys. Acta, 1500: 1-9, 2000.
12. Schilling-Schon, A., Pleyer, U., Hartmann, C., and Rieck, P. W. The role of endogenous growth factors to support corneal endothelial migration after wounding in vitro. Exp. Eye Res., 71: 583-589, 2000.
13. Chesney, J., Metz, C., Bacher, M., Peng, T., Meinhardt, A., and Bucala, R. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol. Med., 5: 181-191, 1999.
14. Ogawa, H., Nishihira, J., Sato, Y., Kondo, M., Takahashi, N., Oshima, T., and Todo, S. An antibody for macrophage migration inhibitory factor suppresses tumour growth and inhibits tumour-associated angiogenesis. Cytokine, 12: 309-314, 2000.
15. Meyer-Siegler, K., and Hudson, P. B. Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology, 48: 448-452, 1996.
16. Shimizu, T., Abe, R., Nakamura, H., Ohkawara, A., Suzuki, M., and Nishihira, J. High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem. Biophys. Res. Commun., 264: 751-758, 1999.
17. White, E. S., Strom, S. R. B., Wys, N. L., and Arenberg, D. A. Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity. J. Immunol., 166: 7549-7555, 2001.
18. Arenberg, D. A., Polverini, P. J., Kunkel, S. L., Shanafelt, A., Hesselgesser, J., Horuk, R., and Strieter, R. M. The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. J. Leukoc. Biol., 62: 554-562, 1997.
19. Strieter, R. M., Kunkel, S. L., Burdick, M. D., Lincoln, P. M., and Walz, A. The detection of novel neutrophil-activating peptide (ENA-78) using a sensitive ELISA. Immunol. Investig., 21: 589-596, 1992.
20. Strieter, R. M., Polverini, P. J., Kunkel, S. L., Arenberg, D. A., Burdick, M. D., Kasper, J., Dzuiba, J., Van Damme, J., Walz, A., Marriott, D., Chan, S., Roczniak, S., and Shanafelt, A. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem., 270: 27348-27357, 1995.
21. Addison, C. L., Daniel, T. O., Burdick, M. D., Liu, H., Ehlert, J. E., Xue, Y. Y., Buechi, L., Walz, A., Richmond, A., and Strieter, R. M. The CXC Chemokine Receptor 2. CXCR2, Is the Putative Receptor for ELR+ CXC Chemokine-Induced Angiogenic Activity. J. Immunol., 165: 5269-5277, 2000.
22. White, E. S., Livant, D. L., Markwart, S., and Arenberg, D. A. Monocyte-fibronectin interactions, via a5bl integrin, induce expression of CXC chemokine-dependent angiogenic activity. J. Immunol., 167: 5362-5366, 2001.
23. Fife, R. S., Sledge, G. W., Jr., Sissons, S., and Zerler, B. Effects of tetracyclines on angiogenesis in vitro. Cancer Lett., 153: 75-78, 2000.
24. Arenberg, D. A., Keane, M. P., DiGiovine, B., Kunkel, S. L., Morris, S. B., Xue, Y. Y., Burdick, M. D., Glass, M. C., Iannettoni, M. D., and Strieter, R. M. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J. Clin. Investig., 102: 465-472, 1998.
25. Arenberg, D. A., Kunkel, S. L., Polverini, P. J., Morris, S. B., Burdick, M. D., Glass, M., Taub, D. T., Iannetoni, M. D., Whyte, R. I., and Strieter, R. M. Interferon-γ-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J. Exp. Med., 184: 981-992, 1996.
26. Arenberg, D. A., Kunkel, S. L., Polverini, P. J., Glass, M., Burdick, M. D., and Strieter, R. M. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J. Clin. Investig., 97: 2792-2802, 1996.
27. Arenberg, D. A., White, E. S., Burdick, M. D., Strom, S. R. B., and Strieter, R. M. Improved survival in tumor-bearing SCID Mice Treated With Interferon-g-Inducible Protein 10 (IP-10/CXCL10). Cancer Immunol. Immunother., 50: 533-538, 2001.
28. Masuya, D., Huang, C., Liu, D., Kameyama, K., Hayashi, E., Yamauchi, A., Kobayashi, S., Haba, R., and Yokomise, H. The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients. Cancer (Phila.), 92: 2628-2638, 2001.
29. Yuan, A., Yang, P. C., Yu, C. J., Chen, W. J., Lin, F. Y., Kuo, S. H., and Luh, K. T. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am. J. Respir. Crit. Care Med., 162: 1957-1963, 2000.
30. Yatsunami, J., Tsuruta, N., Ogata, K., Wakamatsu, K., Takayama, K., Kawasaki, M., Nakanishi, Y., Hara, N., and Hayashi, S. Interleukin-8 participates in angiogenesis in non-small cell, but not small cell carcinoma of the lung. Cancer Lett., 120: 101-108, 1997.
31. Yuan, A., Yu, C. J., Luh, K. T., Kuo, S. H., Lee, Y. C., and Yang, P. C. Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. J. Clin. Oncol., 20: 900-910, 2002.
32. Meyer-Siegler, K. L., Bellino, M. A., and Tannenbaum, M. Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer (Phila.), 94: 1449-1456, 2002.
33. Meyer-Siegler, K. Macrophage migration inhibitory factor increases MMP-2 activity in DU-145 prostate cells. Cytokine. 12: 914-921, 2000.
34. Mitchell, R. A., Liao, H., Chesney, J., Fingerle-Rowson, G., Baugh, J., David, J., and Bucala, R. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response. Proc. Natl. Acad. Sci. USA, 99: 345-350, 2002.
35. Hudson, J. D., Shoaibi, M. A., Maestro, R., Carnero, A., Hannon, G. J., and Beach, D. H. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med., 190: 1375-1382, 1999.
36. Anderson, I. C., Mari, S. E., Broderick, R. J., Mari, B. P., and Shipp, M. A. The angiogenic factor interleukin 8 is induced in non-small cell lung cancer/pulmonary fibroblast cocultures. Cancer Res., 60: 269-272, 2000.
37. Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E. C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., and Seed, B. Tumor induction of VEGF promoter activity in stromal cells. Cell, 94: 715-725, 1998.
38. Lewis, C. E., Leek, R., Harris, A., and McGee, J. O. Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages. J. Leukoc. Biol., 57: 747-751, 1995.
39. Mantovani, A. Tumor-associated macrophages in neoplastic progression: a paradigm for the in vivo function of chemokines. Lab Investig., 71: 5-16, 1994.
40. Smith, D. R., Polverini, P. J., Kunkel, S. L., Orringer, M. B., Whyte, R. I., Burdick, M. D., Wilke, C. A., and Strieter, R. M. Inhibition of IL-8 attenuates angiogenesis in bronchogenic carcinoma. J. Exp. Med., 179: 1409-1415, 1994.
41. Bingle, L., Brown, N. J., and Lewis, C. E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol., 196: 254-265, 2002.